Rhythm Pharmaceuticals, Inc.
RYTM
$59.93
-$0.25-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.70M | 41.83M | 33.25M | 29.08M | 25.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.70M | 41.83M | 33.25M | 29.08M | 25.97M |
| Cost of Revenue | 3.65M | 3.79M | 3.83M | 2.95M | 2.81M |
| Gross Profit | 29.06M | 38.04M | 29.42M | 26.13M | 23.16M |
| SG&A Expenses | 39.09M | 38.13M | 35.38M | 36.42M | 34.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.71M | 83.09M | 77.14M | 69.56M | 73.45M |
| Operating Income | -47.00M | -41.26M | -43.89M | -40.48M | -47.49M |
| Income Before Tax | -49.42M | -43.38M | -43.99M | -31.78M | -141.07M |
| Income Tax Expenses | 80.00K | -90.00K | -344.00K | 479.00K | 300.00K |
| Earnings from Continuing Operations | -49.50M | -43.29M | -43.64M | -32.26M | -141.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.50M | -43.29M | -43.64M | -32.26M | -141.37M |
| EBIT | -47.00M | -41.26M | -43.89M | -40.48M | -47.49M |
| EBITDA | -46.62M | -40.87M | -43.50M | -40.09M | -47.08M |
| EPS Basic | -0.81 | -0.72 | -0.73 | -0.55 | -2.35 |
| Normalized Basic EPS | -0.49 | -0.44 | -0.45 | -0.33 | -0.51 |
| EPS Diluted | -0.81 | -0.72 | -0.73 | -0.55 | -2.35 |
| Normalized Diluted EPS | -0.49 | -0.44 | -0.45 | -0.33 | -0.51 |
| Average Basic Shares Outstanding | 63.06M | 61.60M | 61.22M | 61.01M | 60.14M |
| Average Diluted Shares Outstanding | 63.06M | 61.60M | 61.22M | 61.01M | 60.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |